AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33499916 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygenation (NBO) - high-flow oxygen (8 L/min, 1 hour each time for 6 cycles daily) and low-flow oxygen (2 L/min) for a total of 7 days.
Number of subjects: 150
Study 33499916 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen (2 L/min) by mask for 7 consecutive days (Control group).
Number of subjects: 150
Study 33499916 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygenation (NBO)
Number of subjects: 150
Study 33499916 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen (2 L/min) (Control group)
Number of subjects: 150
Study 32857616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day oral vitamin D supplementation for 4 weeks
Number of subjects: 18
Study 32857616 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μM Tempol
Number of subjects: 18
Study 32857616 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μM apocynin
Number of subjects: 18
Study 32857616 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (control)
Number of subjects: 18
Study 32857616 — intervention group
Group type: EXPERIMENTAL
Intervention: l-NAME (NO synthase inhibitor)
Number of subjects: 18
Study 35134631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (taken three times daily)
Number of subjects: 690
Study 35134631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 34744686 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical activity intervention (twice a week for 45 min, lasting 16 weeks)
Number of subjects: 49
Study 34744686 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical activity intervention
Number of subjects: 49
Study 32889793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health knowledge assessment
Number of subjects: 3091
Study 32889793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health attitude assessment
Number of subjects: 3091
Study 32889793 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about dental hygiene practices
Number of subjects: 3091
Study 32889793 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about diet and oral hygiene
Number of subjects: 3091
Study 32889793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health behaviors and practices
Number of subjects: 3091
Study 32443379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 0
Study 32443379 — intervention group
Group type: COMPARATOR
Intervention: Plain aspirin
Number of subjects: 0
Study 34979429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle plantar flexor force-matching exercises at 5% MVC
Number of subjects: 28
Study 34979429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle plantar flexor force-matching exercises at 20% MVC
Number of subjects: 28
Study 34979429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle plantar flexor force-matching exercises at 50% MVC
Number of subjects: 28
Study 34979429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle plantar flexor force-matching exercises (all target torques)
Number of subjects: 28
Study 33289803 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐ligating brackets (SB)
Number of subjects: 134
Study 33289803 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (CB)
Number of subjects: 134
Study 32706400 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐shaped miniplate osteosynthesis (P2)
Number of subjects: 40
Study 32706400 — intervention group
Group type: COMPARATOR
Intervention: Conventional single miniplate osteosynthesis (P1)
Number of subjects: 40
Study 616636097 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based exposure treatment
Number of subjects: 105
Study 35312562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 66
Study 35312562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34214918 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (in Study 1 and Study 2)
Number of subjects: 356
Study 34214918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in Study 1 and Study 2)
Number of subjects: 356
Study 34214918 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous testosterone (in Study 3)
Number of subjects: 356
Study 35294738 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuwin Ultra+ (CU+) 250 mg
Number of subjects: 24
Study 35294738 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuwin Ultra+ (CU+) 500 mg
Number of subjects: 24
Study 35294738 — intervention group
Group type: COMPARATOR
Intervention: TUR1800 1900 mg
Number of subjects: 24
Study 32927752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking for Vitality (C4V) intervention
Number of subjects: 0
Study 35222592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 180
Study 35222592 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel pad
Number of subjects: 180
Study 35222592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold application)
Number of subjects: 180
Study 32532283 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) associated with conventional cardiac rehabilitation (CR) protocol 7 days a week for 12 weeks
Number of subjects: 0
Study 32532283 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation (CR) protocol
Number of subjects: 0
Study 34794330 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet enriched with 39-60 g/d of mixed nuts (CRDEN) for 8 weeks
Number of subjects: 67
Study 34794330 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted diet without nuts (CRD) for 8 weeks
Number of subjects: 67
Study 33480468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing sex with a regular sexual partner (RSP)
Number of subjects: 75
Study 33480468 — intervention group
Group type: EXPERIMENTAL
Intervention: History of BV
Number of subjects: 75
Study 33480468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with an RSP
Number of subjects: 75
Study 34959823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol-stabilized arginine silicate (ASI) (1.5 g ASI + 12 g dextrose)
Number of subjects: 19
Study 34959823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g dextrose)
Number of subjects: 19
Study 35338064 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Partial Body Weight Support Treadmill Training (FPBWSTT) for 4 weeks, 5 days/week, 45 min/day
Number of subjects: 0
Study 35338064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33234843 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based application of the ABILOCO questionnaire
Number of subjects: 92
Study 33234843 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face application of the ABILOCO questionnaire
Number of subjects: 92
Study 36057768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily)
Number of subjects: 16
Study 36057768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33631385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 47
Study 33631385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 34854695 — intervention group
Group type: EXPERIMENTAL
Intervention: Information session, activity tracker, regular motivational emails
Number of subjects: 126
Study 34854695 — intervention group
Group type: COMPARATOR
Intervention: Control wait‐list group
Number of subjects: 126
Study 33969121 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bracket
Number of subjects: 18
Study 33969121 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐ligating bracket
Number of subjects: 18
Study 33969121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bracket
Number of subjects: 18
Study 32223104 — intervention group
Group type: EXPERIMENTAL
Intervention: SNMS+ECSW
Number of subjects: 65
Study 32223104 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback combined with electrical stimulation (Control)
Number of subjects: 65
Study 34339954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low monoenergetic DECT images
Number of subjects: 45
Study 34339954 — intervention group
Group type: COMPARATOR
Intervention: Conventional images
Number of subjects: 45
Study 32370802 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg/day folic acid
Number of subjects: 60
Study 32370802 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day (6S)-5-methyltetrahydrofolic acid
Number of subjects: 60
Study 35831241 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma therapy (3 application sessions at 15-day intervals)
Number of subjects: 20
Study 34447873 — intervention group
Group type: COMPARATOR
Intervention: Video clips
Number of subjects: 332
Study 34447873 — intervention group
Group type: EXPERIMENTAL
Intervention: Still images
Number of subjects: 332
Study 35636621 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier high
Number of subjects: 350
Study 35636621 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier low-intermediate
Number of subjects: 350
Study 35636621 — intervention group
Group type: COMPARATOR
Intervention: Dose escalation (64 Gy vs 70 Gy)
Number of subjects: 350
Study 33626969 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐55920839 (10 mg/kg IV doses every 2 weeks)
Number of subjects: 0
Study 33626969 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐55920839
Number of subjects: 0
Study 33626969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32618386 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily)
Number of subjects: 9338
Study 32618386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9338
Study 34472194 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcodent painless needle tips
Number of subjects: 30
Study 34472194 — intervention group
Group type: COMPARATOR
Intervention: Regular needle tips
Number of subjects: 30
Study 34293255 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV 1.1
Number of subjects: 26
Study 34293255 — intervention group
Group type: COMPARATOR
Intervention: APV-CMV
Number of subjects: 26
Study 33970700 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty with Bilateral Inferior Turbinoplasty (BIT)
Number of subjects: 80
Study 33970700 — intervention group
Group type: COMPARATOR
Intervention: Septoplasty alone
Number of subjects: 80
Study 33970700 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty with BIT
Number of subjects: 80
Study 32668834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneling without a catheter loop (TG2)
Number of subjects: 150
Study 32668834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneling with a catheter loop (TG1)
Number of subjects: 150
Study 32668834 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 150
Study 32668834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneling techniques (TG1 and TG2)
Number of subjects: 150
Study 32660282 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every-8-weeks
Number of subjects: 837
Study 32660282 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg every-2-weeks
Number of subjects: 837
Study 32660282 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 837
Study 32997575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 418
Study 32997575 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine 1,000 mg/m2 every 3 weeks
Number of subjects: 418
Study 32406770 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (100% equivalent dose with conventional protocol)
Number of subjects: 40
Study 32406770 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (80% equivalent dose)
Number of subjects: 40
Study 32406770 — intervention group
Group type: COMPARATOR
Intervention: Protocol C (64% equivalent dose)
Number of subjects: 40
Study 33593768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive praziquantel (PZQ) treatment: three doses, each 2 weeks apart before BCG immunisation, followed by a dose at week 8 and quarterly thereafter.
Number of subjects: 480
Study 33593768 — intervention group
Group type: COMPARATOR
Intervention: Standard praziquantel (PZQ) treatment: doses at week 8 and 52.
Number of subjects: 480
Study 33593768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive praziquantel (PZQ) treatment
Number of subjects: 480
Study 33593768 — intervention group
Group type: COMPARATOR
Intervention: Standard praziquantel (PZQ) treatment
Number of subjects: 480
Study 33243291 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIDS intervention (fentanyl-specific overdose education, behavior change motivational interviewing sessions, fentanyl test strip training, and distribution of fentanyl test strips for personal use)
Number of subjects: 500
Study 33243291 — intervention group
Group type: COMPARATOR
Intervention: Standard overdose education (control)
Number of subjects: 500
Study 33243291 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIDS intervention
Number of subjects: 500
Study 36125447 — intervention group
Group type: EXPERIMENTAL
Intervention: TRM (δ-tocotrienol 250 mg; resveratrol 150 mg)
Number of subjects: 82
Study 36125447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose 400 mg)
Number of subjects: 82
Study 33484821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 59
Study 33484821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 34281918 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's Holter monitoring for 7 days
Number of subjects: 162
Study 34281918 — intervention group
Group type: COMPARATOR
Intervention: Diary of motor fluctuations for 7 days
Number of subjects: 162
Study 34281918 — intervention group
Group type: COMPARATOR
Intervention: Clinical information collected during consultation
Number of subjects: 162
Study 34281918 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's Holter monitoring
Number of subjects: 162
Study 36068181 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention to increase physical activity in daily living (PADL)
Number of subjects: 49
Study 36068181 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 49
Study 34431871 — intervention group
Group type: EXPERIMENTAL
Intervention: CR with CPAP (10 to 12 cmH2O)
Number of subjects: 20
Study 34431871 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient CR without CPAP (Control Group - CG)
Number of subjects: 20
Study 36473763 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 36473763 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study 32865344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolumn spinal cord stimulation (SCS)
Number of subjects: 115
Study 32865344 — intervention group
Group type: COMPARATOR
Intervention: Monocolumn spinal cord stimulation (SCS)
Number of subjects: 115
Study 32960643 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (21 g over a week, 7 g per day on Monday, Wednesday, and Friday)
Number of subjects: 12
Study 32960643 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (control group)
Number of subjects: 12
Study 35045394 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow trochlear geometry with medialization of tibial tubercle
Number of subjects: 750
Study 35045394 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep trochlear geometry with medialization of tibial tubercle
Number of subjects: 750
Study 34616836 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR2 antagonism with danirixin
Number of subjects: 43
Study 34616836 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study 33012654 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat 150 mg every other day (QOD)
Number of subjects: 46
Study 34384301 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 50 U
Number of subjects: 61
Study 34384301 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 25 U
Number of subjects: 61
Study 34384301 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study 32539786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral non-absorbable antibiotic prophylaxis (OAP) with tobramycin and colistin for three days preoperatively
Number of subjects: 78
Study 32539786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 35723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus kotschyanus extract (0.5 g/day)
Number of subjects: 30
Study 35723850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33783517 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath test using HPPI-TOFMS
Number of subjects: 428
Study 34086513 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program for persons with MS
Number of subjects: 56
Study 34086513 — intervention group
Group type: EXPERIMENTAL
Intervention: Other gym participation
Number of subjects: 56
Study 34086513 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training
Number of subjects: 56
Study 34086513 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific program
Number of subjects: 56
Study 32623088 — intervention group
Group type: EXPERIMENTAL
Intervention: NETOIMS
Number of subjects: 44
Study 32623088 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 36259579 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidomain intervention (16 sessions of 2 hours each, including physical exercise, cognitive training, dietician education, and individualized integrated care)
Number of subjects: 340
Study 36259579 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidomain intervention
Number of subjects: 340
Study 33185585 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor education (checklists of risk factors and handbooks)
Number of subjects: 46
Study 33185585 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 46
Study 33185585 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor education
Number of subjects: 46
Study 35553446 — intervention group
Group type: EXPERIMENTAL
Intervention: TRF with whey protein supplementation (25 g/d)
Number of subjects: 16
Study 35553446 — intervention group
Group type: COMPARATOR
Intervention: Control, TRF
Number of subjects: 16
Study 33909554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 1%
Number of subjects: 40
Study 33909554 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil 5%
Number of subjects: 40
Study 33909554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Cetirizine 1% and Minoxidil 5%)
Number of subjects: 40
Study 32592082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus eluting EluNIR stent
Number of subjects: 104
Study 32592082 — intervention group
Group type: COMPARATOR
Intervention: Control group from BIONICS trial
Number of subjects: 104
Study 35026217 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over Broca's area
Number of subjects: 160
Study 35026217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over Broca's area
Number of subjects: 160
Study 35026217 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) stimulation
Number of subjects: 160
Study 34061178 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided metastatic colorectal cancer patients (n=6856)
Number of subjects: 9277
Study 34061178 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided KRAS wild-type tumors
Number of subjects: 9277
Study 34061178 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided KRAS wild-type tumors receiving anti-EGFR treatment
Number of subjects: 9277
Study 34061178 — intervention group
Group type: COMPARATOR
Intervention: Right-sided metastatic colorectal cancer patients (n=2421)
Number of subjects: 9277
Study 35482567 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexmedetomidine (0.04 mg/kg, IM) + midazolam (3 mg/kg, IM)
Number of subjects: 20
Study 35482567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dexmedetomidine (0.01 mg/kg, IM) + midazolam (3 mg/kg, IM)
Number of subjects: 20
Study 32657946 — intervention group
Group type: EXPERIMENTAL
Intervention: Reltecimod (0.5 mg/kg)
Number of subjects: 290
Study 32657946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 36496349 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP16001 2 mg with gemigliptin (50 mg once-daily) and metformin (1000 mg twice-daily)
Number of subjects: 34
Study 36496349 — intervention group
Group type: COMPARATOR
Intervention: DWP16001 2 mg without gemigliptin and metformin
Number of subjects: 34
Study 32618438 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed 150 mg peficitinib tablet under fasted conditions
Number of subjects: 58
Study 32618438 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed 150 mg peficitinib tablet under fed conditions
Number of subjects: 58
Study 32618438 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed 150 mg peficitinib tablet
Number of subjects: 58
Study 32250337 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered FES during PNF trunk pattern
Number of subjects: 40
Study 32250337 — intervention group
Group type: COMPARATOR
Intervention: PNF trunk pattern
Number of subjects: 40
Study 34749425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive olfactory training (IOT) - twice a day with a 40-odor set for 15 days
Number of subjects: 65
Study 34749425 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 65
Study 33497874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness awareness program (MAP)
Number of subjects: 54
Study 33497874 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (health education program)
Number of subjects: 54
Study 33116470 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy administered to 658 patients (53%)
Number of subjects: 1237